Amicus Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Amicus Therapeutics Reports Strong Growth in 2024, Driven by Galafold and Pombiliti + Opfolda Sales
Amicus Therapeutics' 2024 10-K filing reveals significant revenue growth driven by its key products, Galafold and Pombiliti + Opfolda, alongside strategic pipeline advancements and a solid financial position.
NASDAQ
Amicus Therapeutics secures global rights to its Fabry disease drug, migalastat, from GlaxoSmithKline, with GSK retaining a financial interest through equity and future payments.